Home » Newsletters » The Carlat Psychiatry Report

The Carlat Psychiatry Report

Antidepressant Round-up 2007 (January) | 2007

View Archived Issues

Suicidality and Antidepressants

January 1, 2007

Another study has been published on the controversial issue of whether antidepressants increase the risk of suicidality in children. Read More

Acupuncture for depression? Not

January 1, 2007

In the largest ever randomized controlled trial of acupuncture for depression, the treatment did no better than “non-specific” needling; in fact, it did somewhat worse. Read More

It’s Official: Topamax doesn’t work for Bipolar Disorder

January 1, 2007

It’s been a bad, bad year for Topamax (topiramate). First, the results of four controlled trials of Topamax as monotherapy for mania showed that it outperforms placebo in only two ways: more paresthesia and more weight loss (Kushner et al, Bipolar Disorders 2006;8:15-27). Read More

Deciphering Antidepressant Research

January 1, 2007

I know that you published a famous meta-analysis several years ago in which you compared the remission rates of patients on venlafaxine with SSRIs and placebo. Can you remind us of what that study showed? Read More

SSRI Nonresponse: What to do Next?

January 1, 2007

Here are TCPR’s guidelines for how to deal with SSRI non-response. Read More

STAR-D Results: How do the results help our Depressed Patients?

January 1, 2007

The following imaginary case vignette helps us examine the clinical relevance of the major findings of the STAR-D trial. Read More

Conventionals: Not only cheaper than atypicals, but more effective?

January 1, 2007

The latest results from the CATIE trial indicate that treatment with Trilafon (perphenazine) is not only much cheaper than treatment with SGAs (second generation antipsychotics), but leads to superior overall quality of life for patients. Read More

Should We Still use Atypicals for Alzheimer’s Disease?

January 1, 2007

Only after thinking long and hard about it, according to the long anticipated results from the CATIE-AD trial. In this study, 421 patients with Alzheimer’s Disease were randomized to double-blind treatment with Zyprexa (mean dose, 3.2 mg/day), Seroquel (34.1 mg/day), Risperdal (0.7 mg/day), or placebo. Read More